Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Inotek Pharmaceuticals Corp (ITEK) Closes Week With A Bang After Positive Phase 2 Study Results

Page 1 of 2

It was an excellent day yesterday for the shares of Inotek Pharmaceuticals Corp (NASDAQ:ITEK), as they continued their momentum from their gangbusters Thursday and closed another 14.83% higher on Friday. One of the primary reasons for today’s boost was a price target update from Cowen’s analyst, Ken Cacciatore, who updated his target to $40.00 from an earlier $15.00 price target. Earlier, Inotek Pharmaceuticals Corp (NASDAQ:ITEK) announced its strategy for the phase 3 development trial of its leading Glaucoma drug, trabodenoson. The clinical stage bio-pharmaceutical company had a meeting with the FDA after the end of its second phase of testing for the drug.

David P. Southwell, CEO of Inotek Pharmaceuticals Corp (NASDAQ:ITEK), said, “…We are pleased with the agency’s guidance on the pivotal trial design which will enable a more efficient registration path to potentially bring this novel glaucoma therapy to market for the benefit of patient.” Trabodenoson has shown positive results in the second phase of its clinical study, without any waning effect with extended duration of the treatment.

least competitive medical schools in the US

Mr. Cacciatore gave the reason for this upgrade stating, “This appears unprecedented and we and our consultants believe that the clinical and regulatory risk is now significantly lowered. Phase II data have been compelling – and consistent – and this morning’s disclosure provides us with even greater conviction.”

The shares of Inotek Pharmaceuticals Corp (NASDAQ:ITEK) have grown by 194.17% since its IPO in February 2015, and by even more, 237.48% in the last two days alone. The stock was up by nearly 200% on Thursday following the release of its phase 2 study data for the drug, as well as its aforementioned meeting with the FDA. If its phase 3 study goes through successfully, it could open a new market for the biopharmaceutical company. Hedge funds mostly missed out on the fun, at least according to their known holdings as of March 31. Only two funds tracked by Insider Monkey, Efrem Kamen‘s Pura Vida Investments, and Matthew Halbower‘s Pentwater Capital, had long positions in the company as of that date. Pentwater held 700,000 shares valued at $3.79 million, while Pura Vida held 87,500 shares.

Efrem Kamen
Efrem Kamen
Pura Vida Investments

Earlier this year, Aerie Pharmaceuticals Inc (NASDAQ:AERI) reported successful results in its phase two study of Rhopressa, its own treatment for glaucoma, only to fail in the third phase of clinical trials reported on April 23. The shares of Aerie Pharmaceuticals fell in excess of 70% after the failed study, but the company announced near-future phase 3 trials for another glaucoma drug, Roclatan™. Vicente Anido, Jr., CEO and Chairman of Aerie Pharmaceuticals Inc, expressed his disappointment with Rhopressa while highlighting his plans for Roclatan. He said, “… we are well prepared to commence the quadruple-action RoclatanTM Phase 3 trials later in 2015. As of the end of the first quarter 2015, we had over $179 million of cash and investments on our balance sheet, and are well-financed to proceed with our key strategies.”

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!